ADTX Stock — Aditxt Inc.

Aditxt Inc. (ADTX)

Updated October 16, 2026.

ADTX is a Stock. Its deepest 1-year drawdown was 100.0%.

Aditxt Inc. is a biopharmaceutical company developing diagnostic and therapeutic products focused on immune profiling, cancer detection, and infectious disease treatment. The company's pipeline includes diagnostic tests based on mitochondrial DNA analysis, immunotherapy candidates for autoimmune conditions, and platforms for understanding immune system dysfunction. As an early-stage biopharmaceutical company, it does not currently distribute dividends and is oriented toward investors seeking long-term growth rather than current income.

ADTX performance

Returns are updating. ADTX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 100.0%.

ADTX key facts

Asset type

Stock

Asset class

Equity

Inception date

06/30/2020

Distribution frequency

None

Last close

$0.0013 (as of 2026-10-16)

Market cap

$1,297,370

Average volume

9762594.0

Payout ratio

0.0%

Forward P/E

0.3513

EPS

$1,000,000.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ADTX risks and drawbacks

The deepest 1-year drawdown on record here is 100.0%.

Who may consider ADTX — and who may not

It is a weaker fit for investors who need monthly cash flow (ADTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ADTX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions